199105-17-4 Usage
General Description
2-(4-Benzyl-piperazin-1-yl)aniline is a chemical compound with the molecular formula C18H22N2. It is a member of the piperazine class of compounds, which are commonly used as central nervous system stimulants and antidepressants. This specific compound is a derivative of piperazine and aniline, and it is commonly used in the synthesis of pharmaceutical drugs. It has a benzyl-piperazine group and an aniline group, making it a potent and versatile building block for the development of various drugs and biologically active compounds. Its chemical structure and properties make it a valuable tool in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 199105-17-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,1,0 and 5 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 199105-17:
(8*1)+(7*9)+(6*9)+(5*1)+(4*0)+(3*5)+(2*1)+(1*7)=154
154 % 10 = 4
So 199105-17-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H21N3/c18-16-8-4-5-9-17(16)20-12-10-19(11-13-20)14-15-6-2-1-3-7-15/h1-9H,10-14,18H2
199105-17-4Relevant articles and documents
PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
Paragraph 0076, (2019/01/15)
Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.
Serine derived NK1 antagonists 2: A pharmacophore model for arylsulfonamide binding
Elliott,Broughton,Cascieri,Chicchi,Huscroft,Kurtz,MacLeod,Sadowski,Stevenson
, p. 1851 - 1856 (2007/10/03)
Modifications to the spirocyclic aryl sulfonamide portion of serine derived NK1 antagonists allow a partial pharmacophore model to be developed.